Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil

Transplantation

Volumn 69, Issue 5, 2000, Pages 991-994

  Rostaing, Lionel ^a   Izopet, Jacques ^b   Sandres, Karine ^b   Cisterne, Jean Marc ^a   Puel, Jacqueline ^b   Durand, Dominique ^a  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LIVER ENZYME; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; GRAFT FAILURE; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIREMIA; VIRUS LOAD;

EID: 0034653617     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200003150-00055     Document Type: Article

References (13)

1. Roth D. Hepatitis C virus: the nephrologist's view. Am J Kidney Dis 1995; 25: 3.
2. Morales JM, Campistol JM, Andrés A, Rodicio JL. Hepatitis C virus and renal transplantation. Curr Opin Nephrol Hypertens 1998; 7: 177.
3. Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ. The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 1997; 29: 608.
4. Legendre C, Garrigue V, Le Bihan C, et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667.
5. Bouthot BE, Murphy BVR, Schmid H, Levey AS, Pereira BJG. Long-term follow-up of hepatitis C virus infection among organ transplanted recipients. Transplantation 1997; 63: 849.
6. Vanrenterghem V. The use of mycophenolate mofetil (Cellcept®) in renal transplantation. Nephron 1997; 76: 392.
7. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
8. O'Haír DP, McManus RP, Komorowski R. Inhibition of chronic rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 1994; 58: 1311.
9. Pereira BJG, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799.
10. Roth D, Zucker K, Cirocco R, et al. A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 1996; 61: 886.
11. Vosnides GG. Hepatitis C in renal transplantation. Kidney Int 1997; 52: 843.
12. van der Woude FJ. Mycophenolate mofetil (RS 61443): nothing new under the sun or an important break-through in the field of transplantation? Nephrol Dial Transplant 1995; 10: 1112.
13. Smith KCG, label NM, Catton MG, et al. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998; 13: 160.